Form 4: Tarsus CMO Reports RSU Vesting and Tax-Related Stock Sale

Tarsus Pharmaceuticals' Chief Medical Officer, Elizabeth Yeu Lin, reported the vesting and settlement of restricted stock units and a subsequent 'sell to cover' transaction for tax obligations.

Summary

• Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, Inc., reported transactions involving the company's common stock.
• On December 15, 2025, 6,819 shares of common stock were acquired due to the settlement of vested Restricted Stock Units (RSUs).
• Following this acquisition, Lin directly owned 24,019 shares of common stock.
• On December 16, 2025, 2,078 shares of common stock were disposed of at a price of $79.5 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer, to satisfy tax withholding obligations related to the RSU vesting and was not a discretionary transaction.
• After the sale, Lin directly owned 21,941 shares of common stock.
• Lin also indirectly owns 6,360 shares through a Spouse's Roth IRA and 12,040 shares through a 401(k) Plan.
• Since the last report, 9,506 shares previously held in the Spouse's Roth IRA were transferred to Lin's self-directed IRA, becoming directly owned.
• Lin holds 20,459 unvested Restricted Stock Units (RSUs) directly.
• The RSUs were granted on November 4, 2024, upon Lin's appointment as Chief Medical Officer, with 25% vesting annually on December 15th from 2025 to 2028, subject to continuous service.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and a non-discretionary 'sell to cover' for taxes), which are neutral events and do not indicate a significant positive or negative shift in company fundamentals or executive sentiment.

Positives

• The vesting of 6,819 Restricted Stock Units (RSUs) indicates continued service and compensation for the Chief Medical Officer.
• The RSU grant on November 4, 2024, aligns with the Chief Medical Officer's appointment, demonstrating long-term incentive alignment.

Negatives

• A disposition of 2,078 shares of common stock, even for tax purposes, reduces the Chief Medical Officer's direct ownership in the company.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

NA

Stakeholder Impact

• Shareholders: The transactions represent a routine change in an executive's direct and indirect holdings, with a minor reduction in direct ownership due to tax obligations. No significant impact on overall shareholder value or confidence is expected from this routine filing.
• Employees: The RSU vesting and subsequent tax-related sale are standard compensation practices for executives, reflecting the company's equity incentive programs.

Next Steps

• Future vesting of remaining Restricted Stock Units (RSUs) on December 15th of 2026, 2027, and 2028, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically the vesting of Restricted Stock Units (RSUs) and a non-discretionary 'sell to cover' transaction for tax purposes. Such events are standard for executive compensation and do not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for buying or selling.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Sale, Chief Medical Officer, Elizabeth Yeu Lin, Sell to Cover